1. Home
  2. ZURA vs FPH Comparison

ZURA vs FPH Comparison

Compare ZURA & FPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zura Bio Limited

ZURA

Zura Bio Limited

HOLD

Current Price

$3.71

Market Cap

455.4M

Sector

Health Care

ML Signal

HOLD

Logo Five Point Holdings LLC

FPH

Five Point Holdings LLC

HOLD

Current Price

$5.16

Market Cap

364.6M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZURA
FPH
Founded
2022
2009
Country
United States
United States
Employees
40
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Real Estate
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
455.4M
364.6M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
ZURA
FPH
Price
$3.71
$5.16
Analyst Decision
Buy
Analyst Count
6
0
Target Price
$13.00
N/A
AVG Volume (30 Days)
856.3K
177.0K
Earning Date
05-14-2026
04-23-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$110,020,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$11.40
Revenue Growth
N/A
N/A
52 Week Low
$1.00
$4.60
52 Week High
$7.25
$6.64

Technical Indicators

Market Signals
Indicator
ZURA
FPH
Relative Strength Index (RSI) 37.96 59.61
Support Level $3.25 $4.89
Resistance Level $4.12 $5.35
Average True Range (ATR) 0.25 0.16
MACD 0.00 0.02
Stochastic Oscillator 39.50 86.91

Price Performance

Historical Comparison
ZURA
FPH

About ZURA Zura Bio Limited

Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.

About FPH Five Point Holdings LLC

Five Point Holdings LLC is an owner and developer of mixed-use, master-planned communities in California. It is engaged in developing new communities that, in addition to homesites, include commercial, retail, educational, and recreational elements, as well as civic areas, parks, and open spaces. Its four reportable segments are Valencia, San Francisco, Great Park, and Hearthstone. It derives the majority of revenue from the Great Park segment, which includes Great Park Neighborhoods being developed adjacent to and around the Orange County Great Park, a metropolitan park under construction in Orange County, California.

Share on Social Networks: